Abliva AB Year-End Report January – December 2024
Positive Interim Analysis of the FALCON Study
Press releases
Abliva AB Year-End Report January – December 2023
40 Patients Enrolled in Wave 1 of the FALCON Study | Fast Track Designation for KL1333 | Orphan Drug Designation for NV354 in both US and Europe
Abliva AB Year-End Report January – December 2022
A successful financing enabled the start of the FALCON study with KL1333
Abliva AB Year-End Report January – December 2021
"2021 was a defining year for Abliva, focused on portfolio delivering, de-risking our assets and building relationships as we prepared for success in 2022." - Ellen Donnelly, CEO
Abliva AB Year-End Report January – December 2020
2020 summary
NeuroVive Pharmaceutical AB Year End Report January – December 2019
Important events in 2019 KL1333 NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study NeuroVi ...
NeuroVive Pharmaceutical AB Year End Report January – December 2018
Positioned for clinical progress
NeuroVive Pharmaceutical AB Year End Report January – December 2017
Strong trend for mitochondrial disorder projects
NeuroVive Pharmaceutical AB Year End Report January – December 2016
Important steps forward and new research collaborations
NeuroVive: Year-End Report 1 Jan. 2015 – 31 Dec. 2015
Fourth Quarter (1 Oct. 2015 - 31 Dec. 2015) · Net revenues were SEK 0 (0) and other operating income was SEK 23,000 (8,000). · Loss before tax was SEK -7,366,000 (-17,346,000). · Earnings per share* w ...
NeuroVive: Year-End Report 1 Jan. 2014 till 31 Dec. 2014
Fourth Quarter (1 Oct. 2014 - 31 Dec. 2014) · Net revenues were SEK 0 (0) and other operating income was SEK 8,000 (12,000). · Loss before tax was SEK -17,346,000 (9,169,000). · Earnings per share* we ...
NeuroVive: Year-End Report 1 Jan. 2013 till 31 Dec. 2013
NeuroVive consolidates positioning as leading mitochondrial medicine company